Why the study?
Does a 6-hour continuous infusion of doxorubicin reduce cardiotoxicity compared to a rapid 15-20 minute infusion in patients with metastatic breast or ovarian cancer?
Population
62 consecutive patients with metastatic carcinoma of the breast or carcinoma of the ovary Stage III or IV
Comparison
Doxorubicin continuous infusion over 6 hours vs Doxorubicin rapid infusion over 15 to 20 minutes…
Design
RCT, prospectively randomized
Authors
Loading...
Supports 6-hour doxorubicin infusion to reduce cardiotoxicity in metastatic breast/ovarian cancer; confirms benefit of prolonged over bolus administration.
Does a 6-hour continuous infusion of doxorubicin reduce cardiotoxicity compared to a rapid 15-20 minute infusion in patients with metastatic breast or ovarian cancer?
Administering doxorubicin as a 6-hour continuous infusion rather than a rapid bolus significantly reduces the decline in LVEF and the risk of clinical congestive heart failure.
Shapira et al. (1990) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: